S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in
NASDAQ:ORMP

Oramed Pharmaceuticals Competitors

$8.91
-0.04 (-0.45 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.50
Now: $8.91
$9.43
50-Day Range
$4.31
MA: $7.74
$11.33
52-Week Range
$2.40
Now: $8.91
$11.71
Volume340,832 shs
Average Volume752,549 shs
Market Capitalization$261.69 million
P/E RatioN/A
Dividend YieldN/A
Beta1.98

Competitors

Oramed Pharmaceuticals (NASDAQ:ORMP) Vs. VNDA, KPTI, ORIC, SNDX, ENTA, and VERU

Should you be buying ORMP stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Oramed Pharmaceuticals, including Vanda Pharmaceuticals (VNDA), Karyopharm Therapeutics (KPTI), ORIC Pharmaceuticals (ORIC), Syndax Pharmaceuticals (SNDX), Enanta Pharmaceuticals (ENTA), and Veru (VERU).

Vanda Pharmaceuticals (NASDAQ:VNDA) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends.

Profitability

This table compares Vanda Pharmaceuticals and Oramed Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vanda Pharmaceuticals8.02%4.56%3.88%
Oramed Pharmaceuticals-424.76%-45.93%-30.33%

Institutional and Insider Ownership

97.6% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 6.0% of Oramed Pharmaceuticals shares are held by institutional investors. 5.9% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 16.1% of Oramed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Vanda Pharmaceuticals has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Vanda Pharmaceuticals and Oramed Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vanda Pharmaceuticals14102.00
Oramed Pharmaceuticals00403.00

Vanda Pharmaceuticals currently has a consensus target price of $15.40, indicating a potential downside of 17.43%. Oramed Pharmaceuticals has a consensus target price of $13.3333, indicating a potential upside of 49.64%. Given Oramed Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Oramed Pharmaceuticals is more favorable than Vanda Pharmaceuticals.

Valuation & Earnings

This table compares Vanda Pharmaceuticals and Oramed Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vanda Pharmaceuticals$227.19 million4.51$115.55 million$2.118.84
Oramed Pharmaceuticals$2.71 million96.56$-11,510,000.00($0.56)-15.91

Vanda Pharmaceuticals has higher revenue and earnings than Oramed Pharmaceuticals. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vanda Pharmaceuticals beats Oramed Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Oramed Pharmaceuticals (NASDAQ:ORMP) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Oramed Pharmaceuticals and Karyopharm Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oramed Pharmaceuticals00403.00
Karyopharm Therapeutics01802.89

Oramed Pharmaceuticals currently has a consensus target price of $13.3333, indicating a potential upside of 49.64%. Karyopharm Therapeutics has a consensus target price of $31.1111, indicating a potential upside of 125.12%. Given Karyopharm Therapeutics' higher probable upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Oramed Pharmaceuticals.

Institutional & Insider Ownership

6.0% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 88.6% of Karyopharm Therapeutics shares are held by institutional investors. 16.1% of Oramed Pharmaceuticals shares are held by company insiders. Comparatively, 13.3% of Karyopharm Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Oramed Pharmaceuticals and Karyopharm Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oramed Pharmaceuticals$2.71 million96.56$-11,510,000.00($0.56)-15.91
Karyopharm Therapeutics$40.89 million24.88$-199,590,000.00($3.22)-4.29

Oramed Pharmaceuticals has higher earnings, but lower revenue than Karyopharm Therapeutics. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Oramed Pharmaceuticals has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.

Profitability

This table compares Oramed Pharmaceuticals and Karyopharm Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Oramed Pharmaceuticals-424.76%-45.93%-30.33%
Karyopharm Therapeutics-221.23%-187.66%-56.42%

Summary

Oramed Pharmaceuticals beats Karyopharm Therapeutics on 8 of the 14 factors compared between the two stocks.

ORIC Pharmaceuticals (NASDAQ:ORIC) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Profitability

This table compares ORIC Pharmaceuticals and Oramed Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ORIC PharmaceuticalsN/AN/AN/A
Oramed Pharmaceuticals-424.76%-45.93%-30.33%

Valuation & Earnings

This table compares ORIC Pharmaceuticals and Oramed Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ORIC PharmaceuticalsN/AN/AN/AN/AN/A
Oramed Pharmaceuticals$2.71 million96.56$-11,510,000.00($0.56)-15.91

ORIC Pharmaceuticals has higher earnings, but lower revenue than Oramed Pharmaceuticals.

Analyst Recommendations

This is a summary of current ratings and recommmendations for ORIC Pharmaceuticals and Oramed Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ORIC Pharmaceuticals01602.86
Oramed Pharmaceuticals00403.00

ORIC Pharmaceuticals presently has a consensus price target of $43.4286, indicating a potential upside of 34.04%. Oramed Pharmaceuticals has a consensus price target of $13.3333, indicating a potential upside of 49.64%. Given Oramed Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Oramed Pharmaceuticals is more favorable than ORIC Pharmaceuticals.

Institutional & Insider Ownership

73.4% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 6.0% of Oramed Pharmaceuticals shares are held by institutional investors. 16.1% of Oramed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

ORIC Pharmaceuticals beats Oramed Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Syndax Pharmaceuticals (NASDAQ:SNDX) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Profitability

This table compares Syndax Pharmaceuticals and Oramed Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Syndax Pharmaceuticals-4,656.63%-77.47%-52.27%
Oramed Pharmaceuticals-424.76%-45.93%-30.33%

Valuation and Earnings

This table compares Syndax Pharmaceuticals and Oramed Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syndax Pharmaceuticals$1.52 million656.32$-56,050,000.00($1.84)-13.27
Oramed Pharmaceuticals$2.71 million96.56$-11,510,000.00($0.56)-15.91

Oramed Pharmaceuticals has higher revenue and earnings than Syndax Pharmaceuticals. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

83.8% of Syndax Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.0% of Oramed Pharmaceuticals shares are owned by institutional investors. 9.5% of Syndax Pharmaceuticals shares are owned by company insiders. Comparatively, 16.1% of Oramed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Syndax Pharmaceuticals has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Syndax Pharmaceuticals and Oramed Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Syndax Pharmaceuticals021002.83
Oramed Pharmaceuticals00403.00

Syndax Pharmaceuticals presently has a consensus price target of $27.50, indicating a potential upside of 12.66%. Oramed Pharmaceuticals has a consensus price target of $13.3333, indicating a potential upside of 49.64%. Given Oramed Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Oramed Pharmaceuticals is more favorable than Syndax Pharmaceuticals.

Summary

Oramed Pharmaceuticals beats Syndax Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Oramed Pharmaceuticals (NASDAQ:ORMP) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Profitability

This table compares Oramed Pharmaceuticals and Enanta Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Oramed Pharmaceuticals-424.76%-45.93%-30.33%
Enanta Pharmaceuticals-29.53%-3.75%-3.53%

Valuation and Earnings

This table compares Oramed Pharmaceuticals and Enanta Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oramed Pharmaceuticals$2.71 million96.56$-11,510,000.00($0.56)-15.91
Enanta Pharmaceuticals$122.47 million8.12$-36,170,000.00($0.89)-55.42

Oramed Pharmaceuticals has higher earnings, but lower revenue than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

6.0% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.8% of Enanta Pharmaceuticals shares are owned by institutional investors. 16.1% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 10.9% of Enanta Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Oramed Pharmaceuticals has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Oramed Pharmaceuticals and Enanta Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oramed Pharmaceuticals00403.00
Enanta Pharmaceuticals13402.38

Oramed Pharmaceuticals currently has a consensus target price of $13.3333, indicating a potential upside of 49.64%. Enanta Pharmaceuticals has a consensus target price of $64.6250, indicating a potential upside of 31.03%. Given Oramed Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Oramed Pharmaceuticals is more favorable than Enanta Pharmaceuticals.

Summary

Oramed Pharmaceuticals beats Enanta Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Oramed Pharmaceuticals (NASDAQ:ORMP) and Veru (NASDAQ:VERU) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Oramed Pharmaceuticals and Veru, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oramed Pharmaceuticals00403.00
Veru00403.00

Oramed Pharmaceuticals currently has a consensus target price of $13.3333, indicating a potential upside of 49.64%. Veru has a consensus target price of $19.25, indicating a potential upside of 39.29%. Given Oramed Pharmaceuticals' higher probable upside, research analysts clearly believe Oramed Pharmaceuticals is more favorable than Veru.

Profitability

This table compares Oramed Pharmaceuticals and Veru's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Oramed Pharmaceuticals-424.76%-45.93%-30.33%
Veru-44.55%-23.72%-13.80%

Valuation and Earnings

This table compares Oramed Pharmaceuticals and Veru's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oramed Pharmaceuticals$2.71 million96.56$-11,510,000.00($0.56)-15.91
Veru$42.59 million23.33$-18,970,000.00($0.11)-125.64

Oramed Pharmaceuticals has higher earnings, but lower revenue than Veru. Veru is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Oramed Pharmaceuticals has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500. Comparatively, Veru has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.

Insider and Institutional Ownership

6.0% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 23.3% of Veru shares are owned by institutional investors. 16.1% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 26.1% of Veru shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Veru beats Oramed Pharmaceuticals on 7 of the 12 factors compared between the two stocks.


Oramed Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.4$18.65-3.8%$1.02 billion$227.19 million51.81Gap Down
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$13.82-5.4%$1.02 billion$40.89 million-4.77Insider Selling
Gap Down
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$32.40-7.7%$999.15 millionN/A0.00Upcoming Earnings
Analyst Downgrade
Gap Down
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$24.41-4.6%$997.61 million$1.52 million-12.98Upcoming Earnings
Gap Up
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$49.32-2.6%$994.88 million$122.47 million-27.10
Veru logo
VERU
Veru
1.4$13.82-3.3%$993.82 million$42.59 million-49.36Analyst Report
Increase in Short Interest
Gap Down
Epizyme logo
EPZM
Epizyme
1.7$9.59-0.7%$976.12 million$23.80 million-4.30Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$8.75-6.7%$964.01 million$35.22 million-6.39Earnings Announcement
Analyst Downgrade
News Coverage
Gap Down
Humanigen logo
HGEN
Humanigen
1.7$18.59-3.1%$959.56 millionN/A0.00Upcoming Earnings
Analyst Report
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$22.28-4.8%$956.24 million$4.23 million-16.50Earnings Announcement
Increase in Short Interest
Analyst Revision
News Coverage
Gap Up
Cara Therapeutics logo
CARA
Cara Therapeutics
1.8$18.35-5.0%$914.42 million$19.89 million-8.66Earnings Announcement
Insider Selling
News Coverage
Gap Down
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$23.57-1.8%$901.72 million$230,000.00-10.96News Coverage
Gap Down
Prothena logo
PRTA
Prothena
2.1$22.32-1.3%$891.04 million$810,000.00-8.72Analyst Upgrade
Insider Buying
Gap Down
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$21.57-3.3%$872.57 million$800.40 million20.35High Trading Volume
Gap Up
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.8$7.19-4.0%$871.31 million$322.07 million-6.85News Coverage
ESSA Pharma logo
EPIX
ESSA Pharma
1.1$27.09-6.1%$868.61 millionN/A-25.08Analyst Report
Increase in Short Interest
News Coverage
Gap Up
Radius Health logo
RDUS
Radius Health
1.3$18.61-2.3%$866.24 million$173.32 million-7.63Earnings Announcement
Analyst Report
News Coverage
Gap Down
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.5$22.23-3.8%$845.59 million$14.87 million-8.29News Coverage
Gap Down
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$22.10-1.2%$840.82 millionN/A-7.62Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$18.47-4.7%$839.41 millionN/A0.00Upcoming Earnings
Gap Down
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.7$17.53-2.1%$832.75 million$322.36 million125.21High Trading Volume
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$23.59-10.3%$815.79 million$296.70 million48.14Earnings Announcement
Analyst Downgrade
News Coverage
Gap Down
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$3.37-2.7%$815.72 million$2.22 million-19.82Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
Odonate Therapeutics logo
ODT
Odonate Therapeutics
2.1$21.05-3.1%$812.61 millionN/A-5.37Earnings Announcement
Analyst Revision
News Coverage
Gap Up
Kadmon logo
KDMN
Kadmon
2.0$4.59-0.2%$787.25 million$5.09 million-7.65Upcoming Earnings
News Coverage
AnaptysBio logo
ANAB
AnaptysBio
1.1$28.70-9.5%$784.89 million$8 million-10.59Earnings Announcement
Insider Buying
Analyst Revision
News Coverage
Gap Up
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$27.39-1.1%$763.55 million$148.36 million-7.11Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Provention Bio logo
PRVB
Provention Bio
1.4$12.72-0.9%$718.53 millionN/A-8.54Earnings Announcement
Analyst Report
News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$21.66-6.4%$714.61 million$252 million-2.21Earnings Announcement
Analyst Downgrade
High Trading Volume
Analyst Revision
News Coverage
Gap Down
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$9.40-4.1%$713.72 millionN/A-2.64Earnings Announcement
Analyst Revision
News Coverage
Gap Down
Merus logo
MRUS
Merus
1.4$22.50-8.9%$711.07 million$31.13 million-7.33Gap Up
OrganiGram logo
OGI
OrganiGram
1.2$3.03-1.7%$703.78 million$64.61 million-4.46Unusual Options Activity
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$4.15-0.2%$701.27 million$59.29 million-27.66Upcoming Earnings
Analyst Report
News Coverage
Gap Down
Akouos logo
AKUS
Akouos
1.7$20.37-2.1%$700.38 millionN/A0.00Upcoming Earnings
High Trading Volume
News Coverage
Gap Down
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.6$16.54-1.7%$697.29 million$17.26 million-4.59
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$28.07-2.7%$672.81 million$19.56 million-20.19Analyst Report
Decrease in Short Interest
News Coverage
Gap Down
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$34.86-0.6%$665.02 million$9.64 million-5.68Earnings Announcement
Analyst Revision
News Coverage
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.4$18.68-3.0%$653.93 million$6.83 million-19.26Upcoming Earnings
Analyst Report
BCEL
Atreca
1.7$17.35-2.3%$636.87 millionN/A-6.15Earnings Announcement
News Coverage
Gap Down
Chimerix logo
CMRX
Chimerix
1.3$9.81-8.8%$614.44 million$12.52 million-17.21Earnings Announcement
News Coverage
Gap Down
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$32.87-1.1%$589.75 million$12.69 million-15.80Analyst Report
Insider Selling
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$16.46-1.0%$589.50 millionN/A0.00Upcoming Earnings
Ardelyx logo
ARDX
Ardelyx
1.9$6.45-0.3%$582.10 million$5.28 million-6.39Upcoming Earnings
News Coverage
Gap Down
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.5$44.50-2.9%$579.84 million$195.89 million127.15Upcoming Earnings
Gap Down
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$12.17-12.2%$577.71 millionN/A-4.89Upcoming Earnings
Gap Down
IVA
Inventiva
0.0$15.00-3.6%$575.90 millionN/A0.00High Trading Volume
Gap Down
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$6.77-3.0%$559.03 million$56.50 million0.00Decrease in Short Interest
Gap Down
XBiotech logo
XBIT
XBiotech
1.2$19.00-0.3%$555.96 millionN/A1.32
Geron logo
GERN
Geron
1.4$1.79-1.1%$555.75 million$460,000.00-5.11
IDYA
IDEAYA Biosciences
1.3$19.07-4.7%$554.37 millionN/A-10.14Gap Up
This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.